Quadrant Capital Group’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Quadrant Capital Group’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-593	Closed	-$2.49K	–	2822
2023 Q1	$2.49K	Hold	593	–	–	﹤0.01%	2386
2022 Q4	$3.56K	Sell	593 -188	-24%	-$1.03K	﹤0.01%	2285
2022 Q3	$5K	Buy	781 +188	+32%	+$1.17K	﹤0.01%	2177
2022 Q2	$4K	Buy	+593	New	+$3.04K	﹤0.01%	2080

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Quadrant Capital Group's CTIC Position: Q2 2023 in Review

Quadrant Capital Group sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 593 shares — an estimated $2.49K sold.

Quadrant Capital Group first reported a position in CTIC in Q2 2022 and held it in 4 quarters. The position peaked at $5K in Q3 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Quadrant Capital Group reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Quadrant Capital Group sold 593 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $2.49K.
Quadrant Capital Group first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2022 and held it in 4 quarters.
Quadrant Capital Group's CTI BioPharma Corp. (DE) Common Stock position peaked at $5K in Q3 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Quadrant Capital Group's 13F filing for Q2 2023, filed 10 Aug 2023.